Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due 2025.
Davis Polk also advised the counterparties to convertible note hedge and warrant transactions in connection with the convertible notes offering.
Headquartered in San Diego, California, NuVasive is a leading medical device company in the global spine surgery market, focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its currently marketed product portfolio focuses on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure.
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jeffrey Gould and associate Sarah Kirk. The Davis Polk equity derivatives team included partner John M. Brandow and counsel Faisal Baloch. Partner Po Sit and associate Adam R. Brownstone provided tax advice. Partner David R. Bauer and associate Jennifer Leather provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.